How many pills of baricitinib should be taken a day?

Baricitinib (Baricitinib), known by the trade name Olumiant and others, is animmunomodulatory drug used to treat rheumatoid arthritis, alopecia areata and COVID-19. It acts as a janus kinase (JAK) inhibitor, blocking JAK1 and JAK2 isoforms.

Usual adult doses of baricitinib for the treatment of rheumatoid arthritis:

Dosage: Baricitinib 2 mg once daily
Comments: This drug may be used as monotherapy or in combination with methotrexate or other DMARDs.

Commonly used doses of baricitinib for the treatment of alopecia areata in adults:

Dosage: Baricitinib 2 mg tablets once daily.

If treatment response is inadequate, the dose may be increased to 4 mg once daily.

For patients with near-total or complete scalp hair loss, with or without extensive eyelash or eyebrow hair loss, consider taking 4 mg once daily 4 mg.

When adequate response is achieved, reduce dose to 2 mg once daily.

Baricitinib Treatment Commonly Used Doses for COVID-19

Baricitinib has been approved by the FDA for the treatment of COVID-19 patients 18 years and older who are hospitalized and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Dosage for adults with COVID-19: Baricitinib 4 mg tablet once daily
Duration of treatment: 14 days or until discharge, whichever comes first.

Baricitinib has received Emergency Use Authorization (EUA) from the U.S. FDA for the treatment of COVID-19 patients aged 2 to less than 18 years who are hospitalized and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO.

Dosage in Children with COVID-19 Dosage in Children with COVID-19 (Research Use Only)

2 years to less than 9 years: Baricitinib 2 mg PO once daily.

9 years and older: Baricitinib 4 mg PO once daily.

Baricitinib is not authorized for the treatment of COVID-19 in patients younger than 2 years of age

Duration of treatment:14 days or until discharge.

Baricitinib is currently on the market in China and is included in the domestic Class B medical insurance program. The domestically produced version of baricitinib and the original version of baricitinib marketed in China cost around 1,200 yuan after medical insurance reimbursement. The specific price may vary according to the medical insurance reimbursement ratio in different regions. It is understood that there are many generic versions of baricitinib overseas, and the most cost-effective one only costs two to three hundred yuan. If patients want to know more about the generic version of baricitinib, they can consult a regular overseas medical consulting company.

Overall, baricitinib, as a drug for the treatment of rheumatoid arthritis and alopecia areata, can bring significant results to patients when used under appropriate guidance. However, you also need to pay close attention to possible side effects and risks when using it.